Comprehensive single-cell transcriptomic profiling of the scalp from patients with moderate-to-severe alopecia areata

What is it about?

Alopecia areata is an autoimmune disease in which the body’s own immune system attacks the hair follicles, leading to patchy hair loss or, in more severe cases, loss of all scalp or body hair. In this study, we used a technology called single-cell RNA sequencing, which can determine what genes are amplified in thousands of individual cells at once, to create a detailed map of the scalp in patients with moderate-to-severe alopecia areata. We analyzed more than 40,000 cells from scalp biopsies taken from bald patches, from non-bald scalp in the same patients, and from healthy volunteers without hair loss. We identified several major cell types in the scalp (immune cells, hair follicle and skin cells, blood vessel cells, and supporting structural cells) and explored how their gene activity changed in alopecia areata. We found overactive immune responses involving both type 1 and type 2 pathways, as well as strong signals through JAK/STAT and IL-15 pathways. We also discovered that non-immune cells such as fibroblasts, smooth muscle cells, blood vessel cells, and hair follicle cells show inflammatory and tissue-remodeling signals, especially in patients with the most severe forms of the disease (alopecia totalis/universalis).

Featured Image

Photo by Ian Talmacs on Unsplash

Photo by Ian Talmacs on Unsplash

Why is it important?

Alopecia areata affects millions of people worldwide and can have a major emotional and psychological impact, especially when hair loss is extensive or long-lasting. While new treatments such as JAK inhibitors have recently been approved, we still do not fully understand why some patients develop more severe disease or why certain treatments help some patients but not others. Our study provides the most comprehensive single-cell map of human alopecia areata scalp to date, across different disease severities. It shows that hair loss is driven not only by attack of immune cells but also by crosstalk between immune cells and the surrounding skin, blood vessels, and support cells. In more severe disease, these inflammatory signals are even stronger. By pinpointing which cell types and molecular pathways are most active in mild versus severe disease, including pathways already targeted by current drugs and others that may represent new therapeutic opportunities, our findings help lay the groundwork for better biomarkers, more personalized treatment choices, and potentially novel therapeutic targets for people living with alopecia areata.